Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03460275 | Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03461185 | Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 100 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03446911 |
| Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery |
| unknown |
| Phase 1 / Phase 2 |
| 20 |
| Amsterdam UMC, location VUmcOTHER |
| 0 |
| Feb 27, 2018 |
| clinicaltrials |
| NCT03424759 | Uncommon EGFR AZD9291 | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT03416231 | Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 2 | 20 | Affiliated Hospital of North Sichuan Medical CollegeOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02734524 | A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 104 | Southwest Hospital, ChinaOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02852083 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC(ModuLung) | unknown | Phase 2 | 86 | University Hospital RegensburgOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | unknown | Phase 2 | 40 | Affiliated Hospital of Hebei UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03399669 | The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation | unknown | Phase 2 | 100 | Samsung Medical CenterOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02410369 | Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer | unknown | Phase 2 | 60 | Tokyo UniversityOTHER | 1 | Dec 21, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03341494 | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide | unknown | Phase 2 | 128 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02499614 | Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)(METROS) | unknown | Phase 2 | 80 | Fondazione Ricerca TraslazionaleOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02515435 | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT03065764 | 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | unknown | Phase 2 | 10 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01963195 | Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy | unknown | Phase 2 | 30 | Anhui Medical UniversityOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT03123445 | Endostar First-line Treatment of Advanced NSCLC | unknown | Phase 2 | 150 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03123484 | β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02844114 | Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy(LCKY2015-21(x)) | unknown | Phase 2 | 60 | Gao YajieOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT02714608 | A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 144 | Tasly Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT03074864 | Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC(TREND) | unknown | Phase 2 / Phase 3 | 90 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 50 | Grupo de Investigación y Divulgación OncológicaOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 48 | Wuling OuOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03053856 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03050437 | A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI | unknown | Phase 2 | 96 | Samsung Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01714908 | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21(RECEL) | unknown | Phase 2 | 100 | Jinming YuOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01744925 | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02370017 | Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment(ANKL-2) | unknown | Phase 2 | 68 | The Catholic University of KoreaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT03002844 | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Dec 28, 2016 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02975609 | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02960607 | High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02961270 | Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 11, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT01683175 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | unknown | Phase 2 | 94 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02930954 | Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 180 | Caicun ZhouOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT01771289 | Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02906150 | Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type | unknown | Phase 2 | 140 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02906163 | First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy | unknown | Phase 1 / Phase 2 | 188 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02802540 | Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients | unknown | Phase 2 / Phase 3 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Aug 31, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2018source: clinicaltrials